# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 51-60 of 563 results.
18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Oct 08, 2019
First Received: Apr 20, 2017
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): 18F-FDG PET SCAN, MRI DIFFUSION
Locations: Centre antoine-LACASSAGNE, Nice, France
Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma
Status: Recruiting
Last Changed: Mar 10, 2020
First Received: Jan 29, 2020
Disease(s): Lymphoma, B-Cell
Intervention(s): Rituximab Biosimilar, Pegylated Interferon α-2b
Locations: Department of Medical Oncology, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China
Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Apr 27, 2016
First Received: Apr 27, 2016
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): bendamustine, rituximab
Locations: Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of
Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
Status: Recruiting
Last Changed: Oct 30, 2019
First Received: Jun 28, 2019
Disease(s): Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
Intervention(s): TQB2450
Locations: Peking University First Hospital, Beijing, Beijing, China
Fifth Medical Center of the Chinese People's Liberation Army General Hospital, Beijing, Beijing, China
Peking Union Medical College Hospital, Beijing, Beijing, China
Peking University Third Hospital, Beijin, Beijing, China
Peking Hospital, Beijin, Beijing, China
... and 14 other locations.
A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy
Status: Recruiting
Last Changed: Jun 19, 2020
First Received: Sep 19, 2018
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Mosunetuzumab, Tocilizumab
Locations: University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica, Santa Monica, California, United States
University of Miami Sylvester Comprehensive Center, Miami, Florida, United States
Moffitt Cancer Center Screening and Prevention, Tampa, Florida, United States
Fort Wayne Medical Institute, Fort Wayne, Indiana, United States
University of Maryland Medical Center, Baltimore, Maryland, United States
... and 26 other locations.
Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Dec 14, 2015
First Received: May 20, 2015
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Consolidation involved-site radiotherapy (ISRT), Consolidation involved-field radiotherapy (IFRT), cyclophosphamide, doxorubicin, vincristine, prednisone
Locations: DiDeng, Wuhan, Hubei, China
The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Dec 14, 2015
First Received: May 20, 2015
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Consolidation involved-site radiotherapy (ISRT), Consolidation involved-field radiotherapy (IFRT), cyclophosphamide, doxorubicin, vincristine, prednisone
Locations: DiDeng, Wuhan, Hubei, China
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Jun 17, 2020
First Received: Sep 07, 2017
Disease(s): Diffuse Large B-Cell Lymphoma
Intervention(s): Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Vincristine Placebo, Prednisone, Polatuzumab vedotin Placebo
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Southern Cancer Center, Daphne, Alabama, United States
City of Hope, Duarte, California, United States
Ronald Reagan UCLA Medical Center; Drug Information Center, Los Angeles, California, United States
Georgetown University Medical Center, Washington, District of Columbia, United States
... and 253 other locations.
A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma
Status: Recruiting
Last Changed: Sep 14, 2018
First Received: Jul 06, 2018
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Decitabine
Locations: Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Recruiting
Last Changed: Jun 16, 2020
First Received: May 03, 2019
Disease(s): Diffuse Large B-cell Lymphoma (DLBCL)
Intervention(s): abexinostat
Locations: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
China-Japan Friendship Hospital, Beijing, China
The Fifth Medical Center of Chinese PLA General Hospital (Beijing 302 Hospital), Beijing, China
Peking University Third Hospital, Beijing, China
West China Hospital, Sichuan University, Chengdu, China
... and 19 other locations.